Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine

Acta Neurol Scand. 2004 Jun;109(6):390-2. doi: 10.1111/j.1600-0404.2004.00259.x.

Abstract

Objective: Chemokines are involved in the pathogenesis of multiple sclerosis. The aim of the study was to evaluate the effects of immunosuppressive therapy on production of two proinflammatory chemokines--interleukin-8 (IL-8) and RANTES (regulated on activation, normal T cell expressed and secreted).

Materials and methods: Twenty-five patients with relapsing-remitting multiple sclerosis were treated with 2-chlorodeoxyadenosine (Cladribine), administered subcutaneously in 6 cycles repeated every 5 weeks. IL-8 and RANTES levels were measured by the enzyme-linked immunoassay (ELISA) method in serum and cerebrospinal fluid (CSF) before and after treatment.

Results: After Cladribine treatment the levels of IL-8 decreased significantly in CSF only, whereas the RANTES levels decreased significantly both in CSF and serum.

Conclusion: Our results suggest that Cladribine therapy might modify the circulating level of RANTES.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Chemokine CCL5 / blood*
  • Cladribine / administration & dosage*
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Injections, Subcutaneous
  • Interleukin-8 / blood*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / blood
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / immunology*

Substances

  • Chemokine CCL5
  • Immunosuppressive Agents
  • Interleukin-8
  • Cladribine